Neumora Therapeutics, Inc. announced the initiation of a Phase 1 single ascending dose /multiple ascending dose study evaluating NMRA-266 in healthy adult participants. NMRA-266 is a highly selective positive allosteric modulator of the M4 muscarinic receptor that Neumora is developing as a treatment for schizophrenia and other neuropsychiatric disorders. Neumora believes that as a selective M4 receptor-positive allosteric modulator, NMRA-266 has the potential to deliver antipsychotic efficacy, while minimizing the side effects associated with current antipsychotics and other non-selective muscarinic agonists.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
8.955 USD | -2.13% |
|
-9.55% | -47.21% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-47.21% | 1.46B | |
+33.25% | 51.07B | |
-8.60% | 38.78B | |
+34.61% | 38.61B | |
-8.98% | 27.32B | |
+11.27% | 26.35B | |
-19.27% | 19.46B | |
+39.88% | 13.58B | |
+30.16% | 12.46B | |
-4.19% | 11.75B |
- Stock Market
- Equities
- NMRA Stock
- News Neumora Therapeutics, Inc.
- Neumora Therapeutics, Inc. Announces NMRA-266 IND Clearance and Initiation of Phase 1 Clinical Study